Mitchel Freedman

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

D. Arnold, S. Reingold, C. Pozzilli, 2020, The Lancet Neurology.